EGFR and non-small cell lung carcinoma: Results from the ongoing phase 1 CHRYSALIS study, evaluating amivantamab in combination with lazertinib (a third-generation EGFR TKI) for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR-mutant NSCLC, showed promising effectiveness and an acceptable safety profile (CHRYSALIS, NCT02609776).